Debt-to-EBITDA measures a company's ability to pay off its debt.
Amgen's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2021 was $4,324 Mil. Amgen's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2021 was $28,458 Mil. Amgen's annualized EBITDA for the quarter that ended in Jun. 2021 was $6,776 Mil.
Amgen's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2021 was 4.84.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Amgen's Debt-to-EBITDA or its related term are showing as below:
NAS:AMGN'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.37 Med: 2.79 Max: 4.24
Current: 2.94
During the past 13 years, the highest Debt-to-EBITDA Ratio of Amgen was 4.24. The lowest was 2.37. And the median was 2.79.
Amgen Debt-to-EBITDA Historical Data
The historical data trend for Amgen's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
Amgen Annual Data
|
|
Trend |
Dec11 |
Dec12 |
Dec13 |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
| Debt-to-EBITDA |
|
|
|
|
|
|
2.76 |
2.75 |
2.63 |
2.37 |
2.54 |
|
Amgen Quarterly Data
|
|
Sep16 |
Dec16 |
Mar17 |
Jun17 |
Sep17 |
Dec17 |
Mar18 |
Jun18 |
Sep18 |
Dec18 |
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
| Debt-to-EBITDA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2.63 |
2.51 |
2.69 |
2.74 |
4.84 |
Competitive Comparison
For the Drug Manufacturers - General subindustry, Amgen's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amgen Debt-to-EBITDA Distribution
For the Drug Manufacturers industry and Healthcare sector, Amgen's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Amgen's Debt-to-EBITDA falls into.
Amgen Debt-to-EBITDA Calculation
Debt-to-EBITDA measures a company's ability to pay off its debt.
Amgen's Debt-to-EBITDA for the fiscal year that ended in Dec. 2020 is calculated as
Amgen's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2021) EBITDA data.
Amgen Business Description
Traded in Other Exchanges
Address
One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), and Lumakras (lung cancer). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Executives
| Sugar Ronald D |
director |
10877 WILSHIRE BLVD. SUITE 1650 LOS ANGELES CA 900274 |
| Williams R Sanders |
director |
DUKE UNIVERSITY SCHOOL OF MEDICINE TRENT DRIVE DURHAM NC 27706 |
| Santos Esteban |
officer: EVP, Operations |
ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 |
| Miles Amy E |
director |
PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: MILES AMY E a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;} |
| Kullman Ellen Jamison |
director |
UNITED TECHNOLOGIES CORP 10 FARM SPRINGS ROAD FARMINGTON CT 06032 |
| Grygiel Nancy A. |
officer: SVP & CCO |
ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 |
| Louie Linda H. |
officer: VP, Finance & CAO |
ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 |
| Holley Charles M |
director |
PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: HOLLEY CHARLES M a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;} |
| Griffith Peter H. |
officer: EVP & CFO |
ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 |
| Reese David M |
officer: EVP, Research and Development |
ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 |
| Druker Brian |
director |
ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320-1799 |
| Austin Wanda M |
director |
6001 BOLLINGER CANYON ROAD SAN RAMON CA 94583 |
| Gordon Murdo |
officer: EVP Global Commercial Ops |
C/O BRISTOL-MYERS SQUIBB COMPANY 345 PARK AVE NEW YORK NY 10154 |
| Piacquad David |
officer: SVP, Business Development |
ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320-1799 |
| Patton Cynthia M |
officer: SVP & CCO |
ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320-1799 |
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
My Gurus
0.25(0.12%) Volume: 1,330,863 10:08PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:AMGN has been successfully added to your 